Bank of America Corp DE Buys 1,576,568 Shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA)

Bank of America Corp DE increased its position in shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA - Free Report) by 1,178.9% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 1,710,303 shares of the company's stock after purchasing an additional 1,576,568 shares during the quarter. Bank of America Corp DE owned approximately 0.83% of Taysha Gene Therapies worth $2,959,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. BNP Paribas Financial Markets purchased a new position in Taysha Gene Therapies in the fourth quarter valued at about $41,000. Ameriprise Financial Inc. purchased a new position in Taysha Gene Therapies in the fourth quarter valued at about $40,000. Jane Street Group LLC boosted its stake in Taysha Gene Therapies by 57.6% in the fourth quarter. Jane Street Group LLC now owns 169,575 shares of the company's stock valued at $293,000 after acquiring an additional 62,003 shares during the last quarter. Northern Trust Corp boosted its stake in Taysha Gene Therapies by 6.3% in the fourth quarter. Northern Trust Corp now owns 1,458,732 shares of the company's stock valued at $2,524,000 after acquiring an additional 86,207 shares during the last quarter. Finally, Aquatic Capital Management LLC bought a new stake in shares of Taysha Gene Therapies in the fourth quarter valued at approximately $135,000. 77.70% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on the stock. Canaccord Genuity Group boosted their price target on shares of Taysha Gene Therapies from $8.00 to $9.00 and gave the company a "buy" rating in a research report on Friday, May 16th. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $7.00 target price on shares of Taysha Gene Therapies in a report on Monday, April 28th. JMP Securities upped their target price on shares of Taysha Gene Therapies from $5.00 to $6.00 and gave the stock a "market outperform" rating in a report on Thursday. Citigroup reaffirmed an "outperform" rating on shares of Taysha Gene Therapies in a report on Thursday. Finally, Needham & Company LLC reissued a "buy" rating and issued a $8.00 price target (up previously from $6.00) on shares of Taysha Gene Therapies in a research note on Monday. Eight analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has an average rating of "Buy" and an average target price of $7.29.

Taysha Gene Therapies Trading Up 3.0%

Shares of Taysha Gene Therapies stock traded up $0.08 during trading on Monday, reaching $2.79. The company's stock had a trading volume of 3,288,239 shares, compared to its average volume of 3,012,103. Taysha Gene Therapies, Inc. has a 52-week low of $1.05 and a 52-week high of $4.32. The company has a market cap of $598.91 million, a price-to-earnings ratio of 4.43 and a beta of 0.90. The firm's 50-day moving average is $1.92 and its two-hundred day moving average is $1.90. The company has a quick ratio of 5.51, a current ratio of 5.51 and a debt-to-equity ratio of 0.48.

Taysha Gene Therapies (NASDAQ:TSHA - Get Free Report) last announced its quarterly earnings results on Thursday, May 15th. The company reported ($0.08) earnings per share for the quarter, meeting the consensus estimate of ($0.08). The business had revenue of $2.30 million during the quarter, compared to analysts' expectations of $1.48 million. Taysha Gene Therapies had a negative net margin of 229.67% and a negative return on equity of 106.36%. During the same quarter in the prior year, the company posted ($0.10) EPS. On average, sell-side analysts anticipate that Taysha Gene Therapies, Inc. will post -0.35 earnings per share for the current year.

Taysha Gene Therapies Profile

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.